AMBALALSA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 44/100 — Quality 33 · Valuation 60
| Share price | ₹30.94 |
| Market cap | ₹238 Cr |
| P/E ratio | 13.4 |
| P/B ratio | 1.5 |
| ROE | 19.3% |
| ROCE | 12.4% |
| Book value | ₹20.70 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹202 Cr | ₹18 Cr | 6.0% |
| 2025 | ₹196 Cr | ₹5 Cr | 5.0% |
| 2024 | ₹173 Cr | ₹6 Cr | 3.0% |
| 2023 | ₹170 Cr | ₹11 Cr | 5.0% |
| 2022 | ₹197 Cr | ₹47 Cr | 13.0% |
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Ambalal Sarabhai Enterprises Limited was incorporate